Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change
08/26/08	CA$0.1300	+18.18%
04/26/04	CA$0.1100	-4.35%
03/26/03	CA$0.1150	0.00%
02/26/02	CA$0.1150	+4.55%
01/26/01	CA$0.1100	0.00%

Delayed Quote Toronto S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.1100CAD

Average target price

1.000CAD

Spread / Average Target

+809.09%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Toronto S.E. 01:26:12 09/09/2026 am IST			5-day change	1st Jan Change
0.1300 ^CAD	+18.18%		0.00%	-15.38%

09/09	Seraxis Holdings, Inc. entered into a definitive agreement to acquire Sernova Biotherapeutics Inc in a merger of equals transaction.	CI
17/06	Sernova's Autologous Islet Transplantation Gets Orphan Drug Designation For Type 3c Diabetes Prevention	MT

Market Cap	4.15Cr 3.01Cr 2.59Cr 2.44Cr 2.23Cr 285.73Cr 4.18Cr 29Cr 11Cr 146.07Cr 11Cr 11Cr 463.31Cr	P/E 2026 *	-5.2x	P/E 2027 *	-4.33x
Enterprise Value	4.15Cr 3.01Cr 2.59Cr 2.44Cr 2.23Cr 285.73Cr 4.18Cr 29Cr 11Cr 146.07Cr 11Cr 11Cr 463.31Cr	EV / Sales 2026 *	-	EV / Sales 2027 *	16.6x
Free-Float	89.49%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Toronto S.E.	SVA	End-of-day quote
Toronto S.E.	SVA	Delayed
OTC Markets	SEOVF	Delayed
Tradegate	PSH0	Real-time
Xetra	PSH0	Delayed
Boerse Muenchen	PSH0	Real-time
Deutsche Boerse AG	PSH0	Delayed
Börse Stuttgart	PSH0	Delayed

09/09	Seraxis Holdings, Inc. entered into a definitive agreement to acquire Sernova Biotherapeutics Inc in a merger of equals transaction.	CI
17/06	Sernova's Autologous Islet Transplantation Gets Orphan Drug Designation For Type 3c Diabetes Prevention	MT
12/06	Sernova Biotherapeutics Inc Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026	CI
23/04	Sernova Biotherapeutics Inc announced that it has received CAD 7.564399 million in funding	CI
14/03	Sernova Biotherapeutics Inc Reports Earnings Results for the First Quarter Ended January 31, 2026	CI
05/03	Sernova Biotherapeutics Inc announced that it expects to receive CAD 7.1 million in funding	CI
20/12	Sernova Biotherapeutics Inc Reports Earnings Results for the Full Year Ended October 31, 2025	CI
19/12	Sernova Biotherapeutics Inc Auditor Raises 'Going Concern' Doubt	CI
13/11	Sernova Biotherapeutics Inc announced that it expects to receive CAD 5 million in funding	CI
23/25/23	Sernova Biotherapeutics Inc Appoints John L. Brooks III as Chair of the Board of Directors	CI
16/25/16	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2025	CI
09/25/09	Sernova Partners With Eledon Pharmaceuticals to Advance Potential Functional Cure for Type 1 Diabetes	MT
09/25/09	Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance A Potential Functional Cure for Type 1 Diabetes	CI

Sernova Share Price Toronto S.E.

Stocks

SVA

CA81732W1041

Medical Equipment, Supplies & Distribution

Valuation : Sernova

Chart: Sernova

Latest news : Sernova

Press Releases : Sernova

News in other languages : Sernova

Quotes and Performance

Price Extremes

Managers and Directors : Sernova

Medical Devices & Implants

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

08/09	Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics	AQ
21/07	A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up	AQ
17/06	Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy	AQ
24/04	Sernova Biotherapeutics Announces Closing of Recently Approved Financings	NE
09/04	Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders	NE

15/23/15	Sernova-Telefonkonferenz für Investoren, die ursprünglich für den 15. September geplant war, wird nun auf den 22. September verschoben
13/23/13	Sernova veranstaltet Telefonkonferenzen für Investoren zur Vorstellung der neu ernannten CEO und zur Bekanntgabe eines Updates zur Geschäftsentwicklung
03/23/03	AstraZeneca : accord de recherche avec le canadien Sernova
03/23/03	Sernova kündigt Forschungskooperation mit dem Pharmakonzern AstraZeneca an, um neuartige potenzielle Zelltherapie-Anwendungen zu untersuchen
10/23/10	Sernova präsentiert beim 2023 Cell & Gene Meeting on the Med der Alliance for Regenerative Medicine

1 week	+18.18%
Current month	+18.18%
1 month	+13.04%
3 months	-13.33%
6 months	-18.75%

1 week	0.1	0.15
1 month	0.1	0.15
3 years	0.1	0.83
5 years	0.1	2.22
10 years	0.1	2.87

Manager	Title	Age	Since
Jonathan Rigby CEO	Chief Executive Officer	58	12/08/2024
James Parsons DFI	Director of Finance/CFO	60	11/10/2024
David Burke IRC	Investor Relations Contact	-	11/10/2024

Director	Title	Age	Since
James Parsons BRD	Director/Board Member	60	19/04/2012
Steven Sangha BRD	Director/Board Member	-	24/04/2023
David Paterson BRD	Director/Board Member	-	01/09/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SERNOVA	+18.18%	0.00%	-27.78%	-84.88%	3.01Cr
STRYKER CORPORATION	-8.81%	-14.63%	-29.54%	-4.36%	12TCr
SMITH & NEPHEW PLC	-3.57%	-3.44%	-27.54%	-3.34%	1.21TCr
GLAUKOS CORPORATION	+4.27%	+3.05%	+96.98%	+145.41%	1.05TCr
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+0.15%	+0.31%	-51.21%	-70.21%	417.46Cr
DOUBLE MEDICAL TECHNOLOGY INC.	+0.42%	-2.13%	-24.64%	+37.78%	245.92Cr
INSIGHT LIFETECH CO., LTD.	-0.16%	-3.69%	-	-	193.03Cr
INSPIRE MEDICAL SYSTEMS, INC.	-1.49%	-1.35%	-28.13%	-73.33%	182.37Cr
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	+0.20%	-2.16%	-18.56%	-24.61%	156.29Cr
Average	+0.19%	-1.05%	-13.80%	-9.69%	1.89TCr
Weighted average by Cap.	+1.31%	-6.49%	-20.88%	+4.03%

	2026 *	2027 *
Net sales	-	25L 18.12L 15.6L 14.68L 13.4L 17Cr 25.13L 1.74Cr 67.11L 8.79Cr 68.08L 66.62L 28Cr
Net income	-1.13Cr -81.93L -70.52L -66.35L -60.55L -78Cr -1.14Cr -7.85Cr -3.03Cr -40Cr -3.08Cr -3.01Cr -126.03Cr	-1.39Cr -1.01Cr -86.75L -81.62L -74.49L -96Cr -1.4Cr -9.66Cr -3.73Cr -49Cr -3.79Cr -3.7Cr -155.03Cr
Net Debt	-	-